- Home
- LIXT vs MULN Comparison
LIXT vs MULN Comparison
Compare LIXT & MULN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- MULN
- Stock Information
- Founded
- LIXT 2005
- MULN 2014
- Country
- LIXT United States
- MULN United States
- Employees
- LIXT N/A
- MULN N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- MULN Auto Manufacturing
- Sector
- LIXT Health Care
- MULN Consumer Discretionary
- Exchange
- LIXT Nasdaq
- MULN Nasdaq
- Market Cap
- LIXT 4.1M
- MULN 3.5M
- IPO Year
- LIXT N/A
- MULN N/A
- Fundamental
- Price
- LIXT $2.33
- MULN $0.48
- Analyst Decision
- LIXT
- MULN
- Analyst Count
- LIXT 0
- MULN 0
- Target Price
- LIXT N/A
- MULN N/A
- AVG Volume (30 Days)
- LIXT 18.9K
- MULN 10.5M
- Earning Date
- LIXT 11-12-2024
- MULN 02-11-2025
- Dividend Yield
- LIXT N/A
- MULN N/A
- EPS Growth
- LIXT N/A
- MULN N/A
- EPS
- LIXT N/A
- MULN N/A
- Revenue
- LIXT N/A
- MULN $156,570.00
- Revenue This Year
- LIXT N/A
- MULN N/A
- Revenue Next Year
- LIXT N/A
- MULN N/A
- P/E Ratio
- LIXT N/A
- MULN N/A
- Revenue Growth
- LIXT N/A
- MULN N/A
- 52 Week Low
- LIXT $1.31
- MULN $0.36
- 52 Week High
- LIXT $4.40
- MULN $987.00
- Technical
- Relative Strength Index (RSI)
- LIXT 54.46
- MULN 25.48
- Support Level
- LIXT $2.25
- MULN $0.36
- Resistance Level
- LIXT $2.68
- MULN $0.54
- Average True Range (ATR)
- LIXT 0.23
- MULN 0.17
- MACD
- LIXT 0.01
- MULN 0.02
- Stochastic Oscillator
- LIXT 53.90
- MULN 10.82
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and energy solutions. The company strives to make electric vehicles more accessible by building an end-to-end ecosystem that takes care of all aspects of electric vehicle ownership. The Company owns and partners with several synergistic businesses, all working towards the same goal of creating clean and scalable electric vehicles and energy solutions. The company has two segments Bollinger and Mullen/ELMS, which generates revenue.